Big pharma steps up access, but uneven progress made: report

Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilenya injunction bid: big pharma takeaways

21 June 2022 The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.

Americas

Canada delivers landmark ruling in favour of big pharma

22 February 2022 The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Big pharma steps up access, but uneven progress made: report

More on this story

Editor's picks

Editor's picks

More features